These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

446 related items for PubMed ID: 15793168

  • 1. Emergence of daptomycin resistance in Enterococcus faecium during daptomycin therapy.
    Lewis JS, Owens A, Cadena J, Sabol K, Patterson JE, Jorgensen JH.
    Antimicrob Agents Chemother; 2005 Apr; 49(4):1664-5. PubMed ID: 15793168
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. In vitro activities of tigecycline, daptomycin, linezolid and quinupristin/dalfopristin against glycopeptide-resistant Enterococcus faecium.
    Abb J.
    Int J Antimicrob Agents; 2007 Mar; 29(3):358-60. PubMed ID: 17229553
    [No Abstract] [Full Text] [Related]

  • 4. Emergence of resistance to daptomycin during treatment of vancomycin-resistant Enterococcus faecalis infection.
    Munoz-Price LS, Lolans K, Quinn JP.
    Clin Infect Dis; 2005 Aug 15; 41(4):565-6. PubMed ID: 16028170
    [No Abstract] [Full Text] [Related]

  • 5. Daptomycin for the treatment of enterococcal bacteraemia: results from the Cubicin Outcomes Registry and Experience (CORE).
    Mohr JF, Friedrich LV, Yankelev S, Lamp KC.
    Int J Antimicrob Agents; 2009 Jun 15; 33(6):543-8. PubMed ID: 19201165
    [Abstract] [Full Text] [Related]

  • 6. De novo daptomycin nonsusceptibility in a clinical isolate.
    Lesho EP, Wortmann GW, Craft D, Moran KA.
    J Clin Microbiol; 2006 Feb 15; 44(2):673. PubMed ID: 16455945
    [No Abstract] [Full Text] [Related]

  • 7. Successful treatment of persistent vancomycin-resistant Enterococcus faecium bacteremia with linezolid and gentamicin.
    Noskin GA, Siddiqui F, Stosor V, Kruzynski J, Peterson LR.
    Clin Infect Dis; 1999 Mar 15; 28(3):689-90. PubMed ID: 10194104
    [No Abstract] [Full Text] [Related]

  • 8. E. faecalis vancomycin-sensitive enterococcal bacteremia unresponsive to a vancomycin tolerant strain successfully treated with high-dose daptomycin.
    Cunha BA, Mickail N, Eisenstein L.
    Heart Lung; 2007 Mar 15; 36(6):456-61. PubMed ID: 18005808
    [Abstract] [Full Text] [Related]

  • 9. Failure of daptomycin β-Lactam combination therapy to prevent resistance emergence in Enterococcus faecium.
    Menon V, Davis R, Shackel N, Espedido BA, Beukers AG, Jensen SO, van Hal SJ.
    Diagn Microbiol Infect Dis; 2018 Feb 15; 90(2):120-122. PubMed ID: 29195768
    [Abstract] [Full Text] [Related]

  • 10. Daptomycin therapy for invasive Gram-positive bacterial infections in children.
    Ardura MI, Mejías A, Katz KS, Revell P, McCracken GH, Sánchez PJ.
    Pediatr Infect Dis J; 2007 Dec 15; 26(12):1128-32. PubMed ID: 18043450
    [Abstract] [Full Text] [Related]

  • 11. Mechanisms of resistance to daptomycin in Enterococcus faecium.
    Montero CI, Stock F, Murray PR.
    Antimicrob Agents Chemother; 2008 Mar 15; 52(3):1167-70. PubMed ID: 18180351
    [Abstract] [Full Text] [Related]

  • 12. Daptomycin: from the mountain to the clinic, with essential help from Francis Tally, MD.
    Eisenstein BI, Oleson FB, Baltz RH.
    Clin Infect Dis; 2010 Jan 01; 50 Suppl 1():S10-5. PubMed ID: 20067387
    [Abstract] [Full Text] [Related]

  • 13. Influence of Minimum Inhibitory Concentration in Clinical Outcomes of Enterococcus faecium Bacteremia Treated With Daptomycin: Is it Time to Change the Breakpoint?
    Shukla BS, Shelburne S, Reyes K, Kamboj M, Lewis JD, Rincon SL, Reyes J, Carvajal LP, Panesso D, Sifri CD, Zervos MJ, Pamer EG, Tran TT, Adachi J, Munita JM, Hasbun R, Arias CA.
    Clin Infect Dis; 2016 Jun 15; 62(12):1514-1520. PubMed ID: 27045126
    [Abstract] [Full Text] [Related]

  • 14. In vitro activity of daptomycin against isolates of Staphylococcus aureus and enterococci: first results from Turkey.
    Arslan H, Azap OK, Ergin F, Karaman SO, Oruç E.
    Int J Antimicrob Agents; 2004 Jun 15; 23(6):642-3. PubMed ID: 15194140
    [No Abstract] [Full Text] [Related]

  • 15. Emergence of daptomycin-resistant Enterococcus faecium in a critically ill patient with postoperative intra-abdominal sepsis.
    Ballester F, Pujol I, Cueto P, Rovira C, Iftimie S, Camps J.
    Rev Esp Quimioter; 2015 Apr 15; 28(2):109-10. PubMed ID: 25904519
    [No Abstract] [Full Text] [Related]

  • 16. Successful therapy of treatment-emergent, non-clonal daptomycin-non-susceptible Enterococcus faecium infections.
    King ST, Usery JB, Holloway K, Koeth L, Cleveland KO, Gelfand MS.
    J Antimicrob Chemother; 2011 Nov 15; 66(11):2673-5. PubMed ID: 21846674
    [No Abstract] [Full Text] [Related]

  • 17. Rapid emergence of resistance to linezolid during linezolid therapy of an Enterococcus faecium infection.
    Seedat J, Zick G, Klare I, Konstabel C, Weiler N, Sahly H.
    Antimicrob Agents Chemother; 2006 Dec 15; 50(12):4217-9. PubMed ID: 16982791
    [Abstract] [Full Text] [Related]

  • 18. Daptomycin for the treatment of vancomycin resistant Enterococcus faecium bacteremia.
    Kvirikadze N, Suseno M, Vescio T, Kaminer L, Singh K.
    Scand J Infect Dis; 2006 Dec 15; 38(4):290-2. PubMed ID: 16709529
    [Abstract] [Full Text] [Related]

  • 19. Daptomycin for the treatment of vancomycin-resistant enterococcal infections.
    Grim SA, Hong I, Freeman J, Edwards C, Clark NM.
    J Antimicrob Chemother; 2009 Feb 15; 63(2):414-6. PubMed ID: 19015143
    [No Abstract] [Full Text] [Related]

  • 20. Association of daptomycin use with resistance development in Enterococcus faecium bacteraemia-a 7-year individual and population-based analysis.
    Egli A, Schmid H, Kuenzli E, Widmer AF, Battegay M, Plagge H, Frei R, Achermann R, Weisser M.
    Clin Microbiol Infect; 2017 Feb 15; 23(2):118.e1-118.e7. PubMed ID: 27746397
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.